Enb Therapeutics
Pharmaceuticals, 44 W 4th St, New York, 10012, United States, 1-10 Employees
Phone Number: 12*********
Who is ENB THERAPEUTICS
ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endo...
Read More
-
Headquarters: 44 W 4th St, New York, New York, 10012, United States
-
Date Founded: 2015
-
Employees: 1-10
-
Revenue: $500 Million to $1 Billion
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 6512
|
NAICS Code: 621210 |
Show More
Does something look wrong? Fix it. | View contact records from ENB THERAPEUTICS
ENB Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ENB Therapeutics
Answer: ENB Therapeutics's headquarters are located at 44 W 4th St, New York, 10012, United States
Answer: ENB Therapeutics's phone number is 12*********
Answer: ENB Therapeutics's official website is https://enbpharma.com
Answer: ENB Therapeutics's revenue is $500 Million to $1 Billion
Answer: ENB Therapeutics's SIC: 6512
Answer: ENB Therapeutics's NAICS: 621210
Answer: ENB Therapeutics has 1-10 employees
Answer: ENB Therapeutics is in Pharmaceuticals
Answer: ENB Therapeutics contact info: Phone number: 12********* Website: https://enbpharma.com
Answer: ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month